Huntington disease (HD) is a lethal neurodegenerative disorder caused by expansion of a cAG repeat within the huntingtin (HTT) gene. Disease prevention can be facilitated by preimplantation genetic testing for this monogenic disorder (pGt-M). We developed a strategy for HD pGt-M, involving whole genome amplification (WGA) followed by combined triplet-primed PCR (TP-PCR) for HTT cAG repeat expansion detection and multi-microsatellite marker genotyping for disease haplotype phasing. the strategy was validated and tested pre-clinically in a simulated pGt-M case before clinical application in five cycles of a PGT-M case. The assay reliably and correctly diagnosed all embryos, even where allele dropout (ADo) occurred at the HTT CAG repeat locus or at one or more linked markers. Ten of the 27 embryos analyzed were diagnosed as unaffected. Four embryo transfers were performed, two of which involved fresh cycle double embryo transfers and two were frozen-thawed single embryo transfers. Pregnancies were achieved from each of the frozen-thawed single embryo transfers and confirmed to be unaffected by amniocentesis, culminating in live births at term. This strategy enhances diagnostic confidence for PGT-M of HD and can also be employed in situations where disease haplotype phase cannot be established prior to the start of pGt-M.
Results
comparison of tp-pcR and standard pcR from single cells and single cell WGA product. We first compared the sensitivity and reliability of standard PCR and TP-PCR in detecting HTT alleles of various repeat sizes from single cells and single cell WGA product from four cell lines GM07175 (heterozygous for normal alleles), GM04282 (17 and 75 CAGs), GM05539 (22 and 101 CAGs) and GM09197 (18 and ~180 CAGs). Standard PCR from both genomic DNA and single cells produced preferential amplification favoring the normal alleles, at the expense of the expanded allele in all three HD-affected cell lines (GM04282, GM05539 and GM09197) such that the expanded allele product was either completely absent or was visible but below the basepair calling threshold of the genetic analyzer ( Fig. 1) .
In contrast, TP-PCR from genomic DNA clearly detected both normal and expanded alleles from the four cell lines. Expanded alleles could be easily identified from the continuous stutter peaks extending beyond 150 bp, since TP-PCR product with ≥36 CAG repeats would be indicative of the presence of an expanded allele. TP-PCR from single cells produced irregular peak patterns, which were likely a consequence of the limited DNA template present in a single cell and resulted in greater difficulty in allele sizing, and allele dropout (ADO) of the expanded allele.
When standard PCR and TP-PCR were performed on single cell WGA product, however, detection sensitivity for the expanded allele was significantly improved. Even so, preferential amplification was more pronounced in standard PCR compared to TP-PCR; standard PCR generated much weaker peaks of the expanded allele compared to the distinct peak pattern of the expanded allele observed after TP-PCR. Therefore, TP-PCR is more reliable in detecting expanded alleles and superior to standard PCR as the preferred method for direct expansion mutation detection in whole-genome amplified single cells.
We also noted that the number of repeats obtained from standard PCR products were consistently shorter by ~2 CAG repeats (for normal alleles) and ~3-5 CAG repeats (for expanded alleles) as compared to those determined by counting of TP-PCR fluorescent peaks. In standard PCR, the number of CAG repeats can be determined by subtracting the expected sizes of the repeat-flanking sequences from the fragment size as determined by the GeneMapper software, and dividing the remainder by three. However, the high GC content of these fragments results in accelerated electrophoretic migration and ensuing under-sizing of these fragments compared with average GC content fragments of the same size. The under-sizing of GC-rich fragments in standard PCR can be corrected by using GC-content matched fragments of different lengths to generate a standard curve for mobility correction, which however is tedious and not cost-effective. In contrast, allele sizing from TP-PCR results does not depend on fragment size calculation using internal size standards and is determined by simple counting of the number of peaks after electrophoresis, thus giving a more accurate result. The observed allele sizes agreed with the genotypes of the reference materials as shown previously 30 , demonstrating the accuracy and ease of use of TP-PCR for allele sizing. TP-PCR reliably detects all allele classes, and can precisely size alleles from normal to expanded, with precision sizing limit at ~179 repeats (Fig. 1 ). The major advantage of TP-PCR compared with standard HD PCR, however, lies neither in its ability to size large expansions more precisely, nor in its non-reliance on mobility correction to accurately size a repeat, but in the fact that it avoids the characteristic preferential amplification of normal over expanded alleles that is observed in standard PCR, thus enabling more confident observation of an expanded allele when it is present.
The reproducibility of TP-PCR in accurately genotyping allele sizes was further evaluated using 10 replicates from each of five whole-genome amplified genomic DNAs of NA20248 and NA20208, which carry 17/36 CAGs and 35/45 CAGs, respectively. All 100 TP-PCR reactions generated the correct genotypes, with neither false positive (detection of ≥36 CAG repeats from the 35-repeat intermediate allele of NA20208) nor false negative (detection of ≤35 CAG repeats from the 36-repeat expanded allele of NA20248) observations (data not shown). www.nature.com/scientificreports www.nature.com/scientificreports/ Assay validation on a simulated pGt-M case. The TP-PCR assay, in parallel with multiplex-PCR of a highly polymorphic tridecaplex (13-plex) microsatellite marker panel 32 (Fig. 2 ) will allow the haplotype phase of the disease/mutant allele to be determined during the PGT-M itself, which is especially useful when there are no family members available for a priori haplotype phasing of the disease allele in the affected spouse.
To pre-clinically validate this combined strategy prior to clinical application, we performed a simulated PGT-M cycle by using cell lines from a two-generation HD family. The affected father (GM04776) carries 18 and 44 CAGs, while the mother (GM04820) carries 16 and 17 CAGs (Fig. 3A) . Two flanking markers were fully informative in this couple (HD2362117, HD2417179) while an additional six markers were partially informative (HD2098407, D4S43, D4S126, I1CAHD, HD3615631 and HD3829173) ( Fig. 3B ). To validate this combined strategy for PGT-M of HD, a total of 78 single cells from their three children (28 from GM04738 and 25 each from GM06384 and GM05442) were individually subjected to WGA, and aliquots were separately analyzed by HTT CAG repeat TP-PCR and flanking multi-marker PCR. Amplification success at the HTT CAG locus was 98.7% (77/78), while allele dropout (ADO) rate was 23.4% (18/77). At the microsatellite loci, amplification success ranged from 89.7% to 100% while ADO rates ranged from 0% to 24.7% (Table 1) . ADO rates were within acceptable limits for assays using single cell whole genome amplified DNA as starting template.
The ADO rate of marker HD2417179 was observed to be high relative to the other markers even though it is not the largest marker amplicon, and could be due to a bias introduced by WGA. However, based on the other fully informative and three partially informative markers, haplotype phasing of normal and mutant chromosomes could be established for all cells (Fig. 4 ). Amplification failure at the HTT CAG repeat locus was observed in one cell from GM04738, while ADO was observed in 7, 6, and 5 cells from GM04738, GM06384, and GM05442, respectively, which could render the diagnosis uncertain if the PGT-M strategy relied entirely on direct mutation detection. However, based on the haplotype established by the linked markers, normal and mutant chromosomes could be confidently assigned, and an unambiguous diagnosis could be achieved. Nine cells from GM04738 showed CAG repeat sizes (66-76 CAGs) that differed from that of genomic DNA (65 CAGs), reflecting the relative mitotic instability/mosaicism of expanded alleles compared with normal alleles 33 , which nonetheless had no effect on diagnostic accuracy. The combined direct and indirect mutation detection produced an unambiguous "diagnosis" for all single cells of all three cell lines. GM04738 was "diagnosed" as affected while GM06384 and www.nature.com/scientificreports www.nature.com/scientificreports/ GM05442 were "diagnosed" as unaffected, consistent with their known disease status determined from genomic DNA.
clinical iVf pGt-M of HD. The father was previously genotyped as carrying a normal allele of 18 CAG repeats and an expanded allele of 43 CAG repeats, which we confirmed to within one repeat by TP-PCR (Fig. 5A ). The mother was heterozygous for two normal alleles of 15 and 17 CAG repeats ( Fig. 5A ). Tridecaplex marker analysis identified four fully informative markers (HD2098407, HD2417179, I1CAHD and HD3377975), and seven partially informative markers (D4S3038, D4S43, HD2362117, D4S126, HD3139793, D4S412, and HD3829173) (Figs 5B and 6).
Standalone indirect linkage-based PGT-M was not possible for this couple, due to the unavailability of any family members of the affected spouse, who are required in order for a priori establishment of the disease haplotype phase. Hence, direct detection of the HTT CAG repeat was necessary for this couple, and the Table 1 . Amplification failure and allele dropout rates at the HTT (CAG) n repeat and tridecaplex panel marker loci calculated from GM04738 (n = 28), GM06384 (n = 25), and GM05442 (n = 25) single cells. * calculated from cell line(s) heterozygous at the locus.
multi-microsatellite PCR and genotyping was performed on each embryo in parallel to allow disease haplotype phasing during the PGT-M itself. In total, five IVF PGT-M cycles were performed on this couple, and a summary of all five cycles is shown in Table 2 . For blastomeres carrying the expanded allele, slight differences in allele size (40-46 CAGs) were observed, again reflecting increased instability/mosaicism of expanded alleles. ADO was observed at least once for each marker. For one embryo (#22), one of two blastomeres exhibited amplification failure at the HTT CAG repeat locus and six markers, and ADO of four additional markers (data not shown). Even so, haplotypes could be correctly assigned, as confirmed by concordance analysis with the second blastomere, which exhibited amplification failure of only one marker and ADO of another two markers. Unambiguous haplotype phasing could be established for all 25 embryos with successful genotyping. A total of 10 embryos were diagnosed as unaffected. Four embryo transfers were performed, of which two were fresh double embryo transfers (cycles 1 and 3), and two were frozen-thaw single embryo transfers (cycles 2 and 5). Both frozen-thaw embryo transfers resulted in pregnancies. Prenatal confirmation of unaffected status was performed by amniocentesis, whereby the same normal CAG repeat sizes observed in the embryo were also observed in the fetus (Figs 5 and 6), and both babies were delivered at term.
Discussion
TP-PCR has been shown to provide reliable amplification and detection of repeat expansions regardless of size [25] [26] [27] [28] 30, 34 , and the American College of Medical Genetics and Genomics has indicated that it is the preferred method for genetic testing of HD 35 . Yet, standard PCR is still currently used for direct mutation detection in HD PGT-M [14] [15] [16] [17] [18] [19] [20] . One potential pitfall of standard PCR is that a very large expanded allele may fail to amplify or may amplify insufficiently to be detected due to preferential amplification favoring the normal allele (see Fig. 1 , for example). Although very large expanded alleles are very rare in HD, the risk of failing to detect a large expanded allele, and thus HD affected status, cannot be ignored especially in the context of PGT-M where the affected spouse carries a large expansion that is at risk of further expansion. Additionally, the CAG repeat sizes calculated from standard PCR fragment lengths may not accurately reflect the actual CAG repeat length, frequently under-estimating by 1-2 repeats due to faster electrophoretic migration of GC-rich DNA compared to non GC-rich DNA (see Fig. 1 , for example). In certain situations, such imprecise CAG repeat sizing could lead to ambiguous situations in PGT-M, for example, if the expanded allele in question is 36 or 37 CAG repeats. Methods such as adding additives (Q-solution) and using engineered polymerases (hot start polymerase), which were also employed in our assays, have been shown to improve the performance of standard PCR 24 . Nevertheless, amplification of a large allele in the presence of a much smaller allele is still problematic as shown in Fig. 1 . In contrast, this TP-PCR assay has been optimized to reliably amplify and precisely determine CAG repeat sizes from the smallest normal allele up to expanded sizes of ~179 repeats, without any need for migration mobility correction ( Fig. 1) 29, 30 . Besides, our TP primer design generates the strongest annealing to the furthest position within the repeat region from the opposing flanking primer, therefore generating a tall and distinct last peak representing www.nature.com/scientificreports www.nature.com/scientificreports/ the largest amplicon to allow clear and easy allele sizing (Figs 1 and 2A) , and making it unnecessary to perform extra standard PCR to improve the expansion detection 23, 25, 26 . Despite its unique ability to amplify and detect repeat expansions regardless of size, TP-PCR has not been widely used in PGT-M of many trinucleotide repeat disorders, including HD. In fact, the concept of TP-PCR can easily be modified for application to other diseases caused by expansions of other repeat motifs.
The combination of expansion mutation detection and disease haplotype tracking is especially beneficial for at-risk couples where a priori establishment of disease haplotype phase is not possible due to unavailability of www.nature.com/scientificreports www.nature.com/scientificreports/ samples from additional family members. For this group of couples, direct expansion detection is indispensable in PGT-M. However, if standalone direct expansion mutation detection is employed, ambiguity may arise from ADO of the expanded/mutant allele in cases where parental normal alleles are uninformative. This ADO risk can be reduced, but not entirely eliminated, by testing directly on blastomeres instead of first subjecting them to WGA which is known to increase ADO rates (Harton et al., 2011) , and by testing trophectoderm samples instead of blastomeres. Nonetheless, ADO is best overcome by parallel analysis of a highly polymorphic multi-microsatellite panel of closely linked markers 32 to establish haplotype phase of the disease/mutant allele. For example, haplotype analysis provided a definitive diagnosis when ADO of the affected spouse's expanded HTT allele was observed in embryo 18 of the clinical IVF PGT-M case (Figs 5 and 6 ). The high marker redundancy and polymorphism of the panel also ensure that haplotyping is not compromised when one or more markers experience amplification failure or ADO. For example, amplification failure of as many as six markers and ADO of an additional four markers was observed in one blastomere of embryo 22, in addition to amplification failure at the HTT CAG repeat locus. Nevertheless, the results from the remaining three successfully genotyped markers and the four markers that exhibited ADO was sufficient to establish that the embryo inherited the paternal mutant haplotype and was therefore affected. This diagnosis was confirmed in a second blastomere from the same embryo which produced successful genotyping at the HTT CAG repeat locus and 10 marker loci. The high polymorphism of the www.nature.com/scientificreports www.nature.com/scientificreports/ panel markers also serves to detect exogenous or parental DNA contamination, or even the inheritance of extra parental chromosomes indicative of possible trisomy (e.g. embryo 14, Figs 5 and 6), ensuring higher diagnostic confidence.
As shown throughout all five cycles of the PGT-M case, the combination of the direct mutation detection and the tridecaplex microsatellite marker assay is robust even when applied to whole genome amplified single blastomeres, because haplotype phasing is highly tolerant of random ADO of individual markers when there is ample marker redundancy. Furthermore, this combined assay allows disease/normal haplotypes to be established during the actual PGT-M case, which is useful in cases with no additional affected family members. For instance, in the PGT-M case described above, the disease haplotype (shaded in black in Fig. 6 ) can be inferred by comparing the alleles of the HTT CAG repeat and the informative markers in the parents and in each embryo. Once the disease haplotype phase was determined, the clinical status of each embryo could be subsequently determined. A combined assay not only allows disease/normal haplotype phase determination of each embryo during the PGT-M case itself without the need for extra information from other family members, it also greatly minimizes the "no call" instances caused by ADO of the mutant/expanded HTT CAG repeat and is thus diagnostically superior to standalone direct mutation detection.
For couples with available family members, both the TP-PCR and the tridecaplex marker panel will be useful resources for establishing disease haplotype phase before PGT-M begins, although the direct TP-PCR assay can be omitted during PGT-M analysis of the embryos in favor of the more ADO-resilient multi-marker haplotype-based assay. Another significant proportion of couples seeking PGT-M involve individuals who are at risk for HD but do not wish to know their own disease status, in which case direct mutation detection cannot be utilized. Instead, "exclusion PGT-M" is performed to track transmission of the at-risk partner's at-risk HTT haplotype, which requires availability of the at-risk partner's affected parent to determine the at-risk grandparental haplotype. In this respect, our tridecaplex marker panel was specifically designed and optimized for the HTT locus and all 13 markers are highly polymorphic. Therefore, for couples who desire exclusion testing, the tridecaplex microsatellite marker panel will be a useful resource for determining the at-risk individual's at-risk haplotype, and for tracking the at-risk haplotype during exclusion PGT-M.
Taken together, our optimized TP-PCR assay addresses some limitations in standard PCR and reliably increases diagnostic confidence in PGT-M with minimal steps. This is the first report demonstrating the utility and robustness of TP-PCR of the HTT CAG repeat expansion in HD PGT-M, even when day 3 single blastomere analysis is employed.
Materials and Methods
Biological samples. DNA samples (NA20248 and NA20208) and cell lines of four unrelated individuals (GM07175, GM04282, GM05539 and GM09197) and five members of an HD family (GM04776, GM04820, GM04738, GM06384 and GM05442) were purchased from the Coriell Cell Repositories (CCR, Camden, New Jersey). Fibroblasts were treated with 0.05% trypsin before single cell isolation and processing. Single lymphoblasts and fibroblasts were obtained and processed as described previously 36 . Single cell whole genome amplification (WGA) was performed using either the REPLI-g Single Cell Kit (Qiagen, Germany) or the illustra GenomiPhi ™ V2 DNA Amplification Kit (GE Healthcare, United Kingdom) according to respective manufacturer's instructions. This study was approved by the Institutional Review Board of the National University of Singapore (07-123E). All methods reported in this manuscript were developed and validated in-house and performed in accordance with ESHRE guidelines for PGT-M. tp-pcR, standard pcR, and multiplex microsatellite pcR. TP-PCR, standard PCR, and multiplex microsatellite PCR were performed in separate reactions according to the conditions described below. TP-PCR and subsequent GeneScan analysis were performed as previously described 30 . Briefly, each 25 µl reaction used either 10 ng genomic DNA, 6 µl of lysed and neutralized single cell sample, or 1 µl of whole-genome amplified single cells or 100 pg genomic DNA as template, 1.5x Q-Solution (Qiagen), 1x PCR buffer containing 1.5 mM of MgCl 2 (Qiagen), 0.2 mM deoxyribonucleic triphosphates (Roche Applied Science, Germany), 2 units of HotStar Taq DNA polymerase (Qiagen), 0.5 µM of the F and TAIL primers, and 0.05 µM of TPP primer 30 . When genomic DNA or WGA product was used as template, PCR cycling conditions consisted of an initial polymerase activation step at 95 °C for 15 mins followed by 30 cycles of 98 °C for 45 sec, 63 °C for 1 min, and 72 °C for 2 mins, and a final extension at 72 °C for 5 mins. When single cell samples were used as template, 40 cycles were used.
Standard PCR was performed in a 25 µl reaction containing either 10 ng genomic DNA, 6 µl of lysed and neutralized single cell sample, or 1 µl of single cell WGA product as template, 1 × Q-Solution (Qiagen), 1 × PCR buffer containing 1.5 mM of MgCl 2 (Qiagen), 0.25 mM deoxyribonucleic triphosphates (Roche Applied Science), 1.25 units of HotStar Taq DNA polymerase (Qiagen), and 0.4 µM each of forward 30 and reverse 37 primers. When genomic DNA or WGA product was used as template, PCR cycling conditions consisted of an initial polymerase activation step at 95 °C for 15 mins followed by 30 cycles of 98 °C for 45 sec, 60 °C for 1 min, and 72 °C for 2 mins, and a final extension at 72 °C for 5 mins. When single cell samples were used as template, PCR conditions were identical except that a 2 min extension with a 20-second increment per cycle was applied, and number of cycles was increased to 40.
A 1 µl aliquot of the PCR product was mixed with 9 µl of Hi-Di ™ formamide and 0.3 μl of GeneScan ™ 500 ROX ™ dye size standard. The mixtures were denatured at 95 °C for 5 min, cooled to 4 °C, and resolved in a 3130xl Genetic Analyzer (Applied Biosystems) using a 36 cm capillary filled with POP-4 ™ or POP-7 ™ polymer. The mixture was electrokinetically injected at 1.2 kV for 18 seconds and electrophoresed for 25 minutes at 60 °C. GeneScan analysis was performed with GeneMapper 4.0 software (Applied Biosystems).
